The emerging role of pituitary tumour transforming gene (PTTG) in endocrine tumourigenesis

Molecular and Cellular Endocrinology

Volumn 278, Issue 1-2, 2007, Pages 1-6

  Kim, D S ^a   Fong, J ^a   Read, M L ^a   McCabe, C J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Endocrine cancer; PTTG; Securin

Indexed keywords

GROWTH FACTOR; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CELL METABOLISM; CELL TRANSFORMATION; DNA REPAIR; DNA REPLICATION; ENDOCRINE TUMOR; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HYPOPHYSIS TUMOR; MITOSIS; MOLECULAR CLONING; NONHUMAN; ONCOGENE; PITUITARY TUMOR TRANSFORMING GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TRANSACTIVATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; RATS;

EID: 36549058660     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.08.006     Document Type: Review

References (54)

1. Abbud R.A., Takumi I., Barker E.M., Ren S.G., Chen D.Y., Wawrowsky K., and Melmed S. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol. 19 (2005) 1383-1391
2. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
3. Bernal J., Luna R., Espina A., Lazaro I., Ramon-morales F., Romero F., Arias C., Silva A., Tortolero M., and Pintor-toro J. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet. 32 (2002) 306-311
4. Black W.G., and Welch H.G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328 (1993) 1237-1243
5. Boelaert K., Mccabe C.J., Tannahill L.A., Gittoes N.J., Holder R.L., Watkinson J.C., Bradwell A.R., Sheppard M.C., and Franklyn J.A. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 88 (2003) 2341-2347
6. Boelaert K., Smith V.E., Stratford A.L., Kogai T., Tannahill L.A., Watkinson J.C., Eggo M.C., Franklyn J.A., and Mccabe C.J. PTTG and PBF repress the human sodium iodide symporter. Oncogene 26 (2007)
7. Chao J.I., Hsu S.H., and Tsou T.C. Depletion of securin increases arsenite-induced chromosomal instability and apoptosis via a p53-independent pathway. Toxicol. Sci. 90 (2006) 73-86
8. Chesnokova V., Kovacs K., Castro A.V., Zonis S., and Melmed S. Pituitary hypoplasia in PTTG-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol. Endocrinol. 19 (2005) 2371-2379
9. Chiu S.J., Hsu T.S., and Chao J.I. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol. Lett. 167 (2006) 122-130
10. Cho-Rok J., Yoo J., Jang Y.J., Kim S., Chu I.S., Yeom Y.I., Choi J.Y., and Im D.S. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 43 (2006) 1042-1052
11. Collis S.J., Deweese T.L., Jeggo P.A., and Parker A.R. The life and death of DNA-PK. Oncogene 24 (2005) 949-961
12. Dominguez A., Ramos-morales F., Romero F., Rios R.M., Dreyfus F., Tortolero M., and Pintor-Toro J.A. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17 (1998) 2187-2193
13. Donangelo I., Gutman S., Horvath E., Kovacs K., Wawrowsky K., Mount M., and Melmed S. Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147 (2006) 4781-4791
14. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer. Inst. 82 (1990) 4-6
15. Hamid T., and Kakar S.S. PTTG/securin activates expression of p53 and modulates its function. Mol. Cancer 3 (2004) 18
16. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
17. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
18. Heaney A.P., Horwitz G.A., Wang Z., Singson R., and Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5 (1999) 1317-1321
19. Heaney A.P., Nelson V., Fernando M., and Horwitz G. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J. Clin. Endocrinol. Metab. 86 (2001) 5025-5032
20. Ishikawa H., Heaney A.P., Yu R., Horwitz G.A., and Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. J. Clin. Endocrinol. Metab. 86 (2001) 867-874
21. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., and Weinberg R.A. Effects of an Rb mutation in the mouse. Nature 359 (1992) 295-300
22. Joensuu H., and Klemi P.J. Comparison of nuclear DNA content in primary and metastatic differentiated thyroid carcinoma. Am. J. Clin. Pathol. 89 (1988) 35-40
23. Joensuu H., Klemi P., and Eerola E. DNA aneuploidy in follicular adenomas of the thyroid gland. Am. J. Pathol. 124 (1986) 373-376
24. Kaneshige M. Mice with a targeted mutation in the thyroid hormone beta-receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13209-13214
25. Kho P.S., Wang Z., Zhuang L., Li Y., Chew J.L., Ng H.H., Liu E.T., and Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J. Biol. Chem. 279 (2004) 21183-21192
26. Kim D., Pemberton H., Stratford A., Boelaert K., Watkinson J., Lopes V., Franklyn J., and Mccabe C. Pituitary tumor transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24 (2005) 4861-4866
27. Kim D.S., Franklyn J.A., Boelart K., Eggo M.C., Watkinson J.C., and Mccabe C.J. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibito of DNA binding-3 autocrine pathway. J. Clin. Endocrinol. Metab. 91 (2006) 4603-4611
28. Kim D.S., Franklyn J.A., Stratford A.L., Boelart K., Watkinson J.C., Eggo M.C., and Mccabe C.J. Pituitary tumor transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. J. Clin. Endocrinol. Metab. 91 (2006) 1119-1128
29. Kim C.S., Ying H., Willingham M.C., and Cheng S.Y. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28 (2007) 932-939
30. Kim D.S., Franklyn J.A., Smith V.E., Stratford A.L., Pemberton H.N., Warfield A., Watkinson J.C., Ishmail T., Wakelam M.J., and Mccabe C.J. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA reapir activity. Carcinogenesis 28 (2007) 749-759
31. Kubo K., Yoshimoto K., Yokogoshi Y., Tsuyuguchi M., and Saito S. Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma. Jpn J Cancer Res 82 (1991) 1097-1103
32. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
33. Loeb L., and Springate C. Errors in DNA replication as a basis of malignant change. Cancer Res. 34 (1974) 2311-2321
34. Malik M.T., and Kakar S.S. Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix matalloproteinase2 (MMP-2). Mol. Cancer 5 (2006) 61
35. Marsh D.J., Zheng Z., Zedenius J., Kremer H., Padberg G.W., Larsson C., Longy M., and Eng C. Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res 57 (1997) 500-503
36. Mccabe C.J., Boelaert K., Tannahill L.A., Heaney A.P., Stratford A.L., Khaira J.S., Hussain S., Sheppard M.C., Franklyn J.A., and Gittoes N.J. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 87 (2002) 4238-4244
37. Mccabe C.J., Khaira J.S., Boelaert K., Heaney A.P., Tannahill L.A., Hussain S., Mitchell R., Olliff J., Sheppard M.C., Franklyn J.A., and Gittoes N.J. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin. Endocrinol. (Oxf.) 58 (2003) 141-150
38. Nagao K., Adachi Y., and Yanagida M. Separase-mediated cleavage of cohesin at interphase is required for DNA repair. Nature 430 (2004) 1044-1048
39. Pei L., and Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11 (1997) 433-441
40. Romero F., Multon M.C., Ramos-morales F., Dominguez A., Bernal J.A., Pintor-toro J.A., and Tortolero M. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 29 (2001) 1300-1307
41. Romero F., Gil-Bernabe A.M., Saez C., Japon M.A., Pintor-toro J.A., and Tortolero M. Securin is a target of the UV response pathway in mammalian cells. Mol. Cell Biol. 24 (2004) 2720-2733
42. Saez C., Asuncion M., Castilla C., Soto A., Navarro E., Tortolero M., Pintor-toro J.A., and Japon M.A. Prognistic significance of human pituitary tumor transforming gene immunohistochemcal expression in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 91 (2006) 1404-1409
43. Sanchez-Puig N., Veprintsev D.B., and Fersht A.R. Human full-length Securin is a natively unfolded protein. Protein Sci. 14 (2005) 1410-1418
44. Smanik P.A., Ryu K.Y., Theil K.S., Mazzaferri E.L., and Jhiang S.M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138 (1997) 3555-3558
45. Tanaka K., Otsuki T., Sonoo H., Yamamoto Y., Udagawa K., Kunisue H., Arime I., Yamamoto S., Kurebayashi J., and Shimozuma K. Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR. Eur J Endocrinology 142 (2000) 340-346
46. Vousden K.H. p53: death star. Cell 103 (2000) 691-694
47. Ward L.S., Brenta G., Medvedovic M., and Fagin J.A. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J. Clin. Endocrinol. Metab. 83 (1998) 525-530
48. Ying H. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 24 (2003) 1467-1479
49. Yu R., Heaney A.P., Lu W., Chen J., and Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 275 (2000) 36502-36505
50. Yu R., Lu W., Chen J., Mccabe C.J., and Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 144 (2003) 4991-4998
51. Zedenius J., Wallin G., Svensson A., Grimelius L., Hoog A., Lundell G., Backdahl M., and Larsson C. Allelotyping of follicular thyroid tumors. Hum. Genet. 96 (1995) 27-32
52. Zhang X., Horwitz G.A., Prezant T.R., Valentini A., Nakashima M., Bronstein M.D., and Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 13 (1999) 156-166
53. Zhou Y., Mehta K.R., Choi A.P., Scolavino S., and Zhang X. DNA damage-induced inhibition of securin expression is mediated by p53. J. Biol. Chem. 278 (2003) 462-470
54. Zou H., Mcgarry T.J., Bernal T., and Kirschner M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 (1999) 418-422